# Appendix E Reporting proforma for pancreatic neuroendocrine neoplasms

# resections

Surname: ………………………… Forename(s): ……………………….. Date of Birth: …………… Sex: ………..

Hospital: …………………………….……………. Hospital No: ………………….……. NHS No: .…………………

Date of Surgery: ……………….… Date of Report Authorisation: …………… Report No: ..……………………...

Date of Receipt: ………………... Pathologist: ………………….…………… Clinician: ………………………........

**MACROSCOPIC EXAMINATION**

**Type of specimen**

Enucleation Local resection

Pancreatoduodenectomy (Whipple resection) Distal pancreatectomy

Total pancreatectomy Pylorus-preserving PD

Not specified Other

Other (specify) ………………………

**Specimen dimensions Site of tumour (select all that apply)**

Length of duodenum …… mm Pancreatic head 

Length of lesser curve stomach ....... mm Uncinate process ****

Length of greater curve stomach ....... mm Pancreatic neck 

Length of small bowel ....... mm Pancreatic body 

Length of gall bladder ....... mm Pancreatic tail 

Length of bile duct ....... mm Other

Size of pancreas ....... x ....... x .......mm Other (specify)……………………………………..

Other (specify) ............................................... mm

**Tumour perforation** Present Not identified

v

**Number of tumours** SingleMultipleIf multiple, state number of tumours……… **Maximum tumour dimension** .............mm (of largest if multiple)

v

**Distance tumour to nearest cut margin** ..……..mm

**Named vessel (if applicable)** Present  Not identified  Which vessel? ...............

**Stent in place** Present  Not identified 

**MICROSCOPIC EXAMINATION**

**Histologic type and grade Proliferative activity**

Well-differentiated, NET G1 **Mitotic count** ……………/2 mm2

Well-differentiated, NET G2 Cannot be determined (explain): ….………………

Well-differentiated, NET G3 Not applicable

Well-differentiated, grade cannot be assessed **Proliferation index with Ki-67** ………………….

Poorly differentiated NEC G3, small cell Cannot be determined (explain): ………………….

Poorly differentiated NEC G3, large cell Not applicable

Poorly differentiated NEC, NOS

Mixed NE non-NE neoplasm (MiNEN) **Presence of necrosis**

Gangliocytic paraganglioma Present Not identified

Other

Other (specify) …………………………………………

**PATHOLOGIC STAGE CLASSIFICATION: ENETS TNM 2006 (Appendix A)**

**TNM descriptors (required only if applicable) (select all that apply)**

m (multiple tumours)

r (recurrent)

y (post-treatment)

**Maximum extent of invasion (pT)**

pTX Primary tumour cannot be assessed

pT0 No evidence of primary tumour

pT1 Tumour limited to the pancreas\* and size <20 mm

pT2 Tumour limited to the pancreas\* and size 20–40 mm

pT3 Tumour limited to the pancreas\* and size >40 mm

pT4 Tumour invading the wall of large vessels\*\* or adjacent organs\*\*\*

\*Limited to the pancreas means there is no invasion of adjacent organs or the wall of large vessels. Extension of tumour into peripancreatic adipose tissue is NOT a basis for staging.

\*\*Large vessels may include coeliac axis and superior mesenteric artery.

\*\*\*Adjacent organs may include stomach, spleen, colon and adrenal gland.

For multiple tumours with different Ts, use the highest.

**Tumour involvement of margins**

**Margin status Involved Not involved Not sampled Not applicable Clearance\***

Gastric transection margin: ….… mm

Duodenal transection margin: .…… mm

Pancreatic transection margin: ….… mm

Bile duct transection margin: ….… mm

SMV/SMA dissection margin: ….… mm

Posterior dissection margin: .....… mm

Anterior pancreatic surface: ….… mm

\*Specify clearance of closest margin(s)

**Named vessel status**:

If named vessel involved, specify …………….

**Resection status**

Complete resection at all surgical margins?

Yes (R0) No, microscopic (R1) No, macroscopic (R2)

**Metastatic spread**

Number of lymph nodes present ………………….

Number of involved lymph nodes …………………

TNM N category:

pNX Regional lymph node status cannot be assessed

pN0 Regional lymph nodes not involved

pN1 Regional lymph nodes involved

**Lymphovascular invasion** Present Not identified Cannot be assessed

**Perineural invasion** Present Not identified Cannot be assessed

**Tumour deposit** Present Not identified Cannot be assessed

**Histologically confirmed distant metastases (pM1):**

Present If present, site: ....…………… Not identified 

(PUL: pulmonary; HEP: hepatic; OSS: osseous)

**Peptide hormone content**

Immunostaining performed Yes No

If yes, peptide identified:

Insulin Yes No

Glucagon Yes No

Somatostatin Yes No

Pancreatic polypeptide Yes No

Gastrin Yes No

Other Yes No

Other (specify)…………………….

**Background abnormalities**

Present

None identified

Islet cell microadenomatosis Present Not identified N/A

Chronic pancreatitis Present Not identified N/A

Other findings identified Yes No 

If yes, specify………………………………………………………………………..

**Signature: …………………….…….. Date: .…../…../……. SNOMED codes: ………………………………**